On Monday, Zealand Pharma shares were the biggest risers on the STOXX 600 index, following positive results from a treatment developed with Boehringer Ingelheim for metabolic steatohepatitis (MASH).

Zealand Pharma announced this morning that its partner Boehringer Ingelheim had observed that up to 83% of adult patients treated with its survodutide (BI 456906) achieved a 'statistically significant improvement' in their health in a phase 2 clinical trial.

The study thus met its primary endpoint at 48 weeks, as well as its secondary endpoint of statistically significant improvement in liver fibrosis.

Following these results, Boehringer has expressed its intention to advance trials in MASH as quickly as possible, having recently initiated a Phase 3 study in the field of obesity.

MASH is also known as NASH (non-alcoholic steatohepatitis).

Boehringer Ingelheim and Zealand Pharma are jointly financing the clinical development of survodutide, which is being fully funded by Boehringer Ingelheim.

It is subject to an accelerated approval procedure in the USA by the FDA in MASH.

Following these announcements, Zealand Pharma's share price rose by over 20% on Monday.

Copyright (c) 2024 CercleFinance.com. All rights reserved.